Low Density Lipoprotein from Human Plasma, BODIPY™ FL complex (BODIPY™ FL LDL)
Citations & References (19)
Invitrogen™
Low Density Lipoprotein from Human Plasma, BODIPY™ FL complex (BODIPY™ FL LDL)
Human low-density lipoprotein (LDL) is large protein complex (∼500,000 Da) that binds to a specific receptor on the surface ofRead more
Have Questions?
Catalog Number
Quantity
L3483
200 μL
Catalog number L3483
Price (CNY)
8,184.00
Each
Add to cart
Quantity:
200 μL
Price (CNY)
8,184.00
Each
Add to cart
Human low-density lipoprotein (LDL) is large protein complex (∼500,000 Da) that binds to a specific receptor on the surface of vertebrate cells and delivers cholesterol via receptor-mediated endocytosis—our labeled LDL complexes are useful tools for studying this phenomenon. These experiments are typically performed by adding fluorescently labeled LDL to cultured cells and analyzing them by microscopy or flow cytometry. Alternatively the fluorescently labeled LDL can be injected into test animals, and the distribution of the label can be analyzed after the specified time period. We offer an unlabeled LDL and two classes of labeled LDLs: those containing an unmodified apoprotein (used to study normal cholesterol delivery and internalization) and those with an acetylated (Ac) apoprotein (used to study cell types that express receptors specific for this acetylated version (i.e., endothelial and microglial cells)).
Fresh LDL Produced Continually We prepare our LDL and AcLDL products from fresh human plasma approximately every two months. The nonacetylated LDL products are shipped within two weeks of their preparation. All acetylated LDL products are available on a continuous basis.
Nonacetylated vs. Acetylated LDL LDL containing an unmodified apoprotein is used to study normal cholesterol delivery and internalization. If the lysine residues of LDL’s apoprotein have been acetylated, the LDL complex no longer binds to the LDL receptor, but rather is taken up by endothelial and microglial cells that possess “scavenger” receptors specific for that modified form.
Key Applications for Labeled LDL Some of the many applications for labeled LDL complexes include: • Counting cell-surface LDL receptors, and analyzing their motion and clustering following internalization • Quantitating LDL receptor activity in fibroblasts (replacing the radiolabeled LDL assay) • Investigating LDL expression and identifying LDL receptor deficiencies in various cell lines
For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Concentration1 mg⁄ml
Detection MethodFluorescence
Dye TypeBODIPY Dyes
FormLiquid
Quantity200 μL
Shipping ConditionWet Ice
Product LineBODIPY
Product TypeSupplement
Unit SizeEach
Contents & Storage
Store in refrigerator (2–8°C) and protect from light.
Frequently asked questions (FAQs)
Can the LDL in BODIPY FL dye-labeled LDL be oxidized?
We do not recommend doing this as the oxidation process (such as oxidation with copper sulphate) may result in the degradation of the BODIPY FL dye.
Can I use methanol or acetone for fixation of cells stained with BODIPY FL LDL?
If the BODIPY FL LDL is applied to live cells first and then fixed, the use of methanol or acetone fixation is not recommended. Exposure to alcohols, acetone, and other organic solvents can dissociate the BODIPY FL dye from the LDL.
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
Authors:Zelcer N, Hong C, Boyadjian R, Tontonoz P,
Journal:Science
PubMed ID:19520913
'Cellular cholesterol levels reflect a balance between uptake, efflux, and endogenous synthesis. Here we show that the sterol-responsive nuclear liver X receptor (LXR) helps maintain cholesterol homeostasis, not only through promotion of cholesterol efflux but also through suppression of low-density lipoprotein (LDL) uptake. LXR inhibits the LDL receptor (LDLR) pathway ... More
Specific binding of human low-density lipoprotein to the surface of schistosomula of Schistosoma mansoni and ingestion by the parasite.
Authors:Bennett MW, Caulfield JP
Journal:Am J Pathol
PubMed ID:2024706
'Low-density lipoproteins (LDL) may be important in human schistosomiasis because LDL bound to the surface of the parasite inhibits the binding of anti-schistosomal antibodies. Low-density lipoproteins also may serve as a source of lipids for the parasite membrane synthesis. Here LDL fluorescently labeled with carbocyanine dye (DiI-LDL) was used to ... More
An actin cytoskeleton with evolutionarily conserved functions in the absence of canonical actin-binding proteins.
Giardia intestinalis, a human intestinal parasite and member of what is perhaps the earliest-diverging eukaryotic lineage, contains the most divergent eukaryotic actin identified to date and is the first eukaryote known to lack all canonical actin-binding proteins (ABPs). We sought to investigate the properties and functions of the actin cytoskeleton ... More
Beta2 integrins modulate the initiation and progression of atherosclerosis in low-density lipoprotein receptor knockout mice.
Authors:Merched A, Tollefson K, Chan L,
Journal:Cardiovasc Res
PubMed ID:19843511
Beta2 integrin-mediated adhesion is thought to be a key event in cardiovascular disease. However, results of clinical trials targeting these molecules have been disappointing. Here, we investigated the effect of inactivation of beta2 integrins at different stages of atherosclerosis by timed bone marrow transplantation (BMT) of CD18(-/-) cells in low-density ... More
Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.
Authors:Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA,
Journal:Blood
PubMed ID:15161671
Cholesterol levels are abnormally increased in many acute myeloid leukemia (AML) samples exposed in vitro to chemotherapy. Blocking these acute cholesterol responses selectively sensitizes AML cells to therapeutics. Thus, defining the molecular mechanisms by which AML cells accomplish these protective cholesterol increments might elucidate novel therapeutic targets. We now report ... More